Waiv, formerly Owkin Dx

Waiv, formerly Owkin Dx

Hundreds of novel innovations enter clinical development each year, while biomarker testing complexity and costs surge. As healthcare shifts toward precision care, treatment decisions, monitoring strategies, and patient pathways increasingly rely on high-dimensional data and advanced diagnostics.

Clinical diagnostics must keep pace with the scale and complexity of precision medicine, ensuring no patient is left behind. Waiv capitalizes on its industry-leading AI stack and clinically validated, AI tests to unlock morphological insights and future-proof the clinical diagnostic workflow.

Breast Cancer, Gastrointestinal (Colorectal) Cancer, Biomarkers, Biotechnology, Medical Devices/Equipment/Supplies, Personalized Medicine, Artificial Intelligence

Yes